MK-4464 / Merck (MSD), Dragonfly Therap - LARVOL DELTA

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed | N=260 ➔ 64 | Trial completion date: Mar 2026 ➔ Sep 2025 | Trial primary completion date: Mar 2026 ➔ Sep 2025

Enrollment change • Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (clinicaltrials.gov) - P1 | N=260 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Jul 2026 ➔ Mar 2026 | Trial primary completion date: Jul 2026 ➔ Mar 2026

Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Preclinical pharmacokinetics and pharmacodynamics of MK-4464, a novel NK cell engager targeting CEACAM5 (AACR 2025) - P1 | "These findings collectively demonstrate the potent and specific activity of MK-4464 in targeting and killing CEACAM5-expressing tumor cells through NK cell activation and cytokine release. These preclinical studies facilitated the clinical translation of MK-4464 and [89Zr]MK-4464 (ClinicalTrials.gov ID NCT05514444)."

PK/PD data • Preclinical • Oncology • CD34 • CEACAM5 • FCGR3A • IFNG • LAMP1 • NKG2D

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (clinicaltrials.gov) - P1 | N=260 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2027 ➔ Jul 2026 | Trial primary completion date: Oct 2027 ➔ Jul 2026

Combination therapy • Enrollment closed • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor